13th Mar 2023 07:30
Instem plc
("Instem", the "Group" or the "Company")
No Exposure to Silicon Valley Bank
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, notes media reports indicating the closure of Silicon Valley Bank ("SVB"). The Company does not hold any cash at SVB and it does not have a banking relationship with or any exposure to SVB.
For further information, please contact:
Instem plc | Via Walbrook |
Phil Reason, CEO | |
Nigel Goldsmith, CFO | |
Singer Capital Markets (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
Peter SteelAlex Bond Oliver Platts | |
Stifel Nicolaus Europe Limited (Joint Broker) | +44 (0) 20 7710 7600 |
Ben Maddison |
|
Alex Price Richard Short |
|
|
|
Walbrook Financial PR | +44 (0) 20 7933 8780 |
Tom Cooper | |
Nick Rome Joe Walker | |
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.
To learn more about Instem solutions and its mission, please visit www.instem.com
Related Shares:
INS.L